📰 Inborn Errors News
Page 3 - Inborn Errors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Inborn Errors. Real-time updates on events, politics, business and more.
January 26, 2023
A recent market research report added to repository of MR Accuracy Reports is an in-depth analysis of global B-hydroxybutyric Acid (Ket
January 17, 2023
FBX-101 is granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) after review of Phase 1/2 RESKUE clinical trial safety and efficacy data PRIME designation
November 3, 2022
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
September 16, 2022
Let’s start up with the current stock price of Orchard Therapeutics plc (ORTX), which is $0.47 to be very precise. The Stock rose vividly during the last session to $0.5099 after opening rate of $0.497 while the lowest price it went was recorded $0.4875 before closing at $0.49.Recently in News on
September 16, 2022
At the end of the latest market close, Aeglea BioTherapeutics Inc. (AGLE) was valued at $0.48. In that particular session, Stock kicked-off at the price of $0.48 while reaching the peak value of $0.54 and lowest value recorded on the day was $0.4797. The stock current value is $0.53.Recently in News
September 13, 2022
The FDA has accepted for Priority Review the Biologics License Application (BLA) for velmanase alfa for the treatment of alpha-mannosidosis.
September 2, 2022
Results from the clinical development programme developed with Protalix BioTherapeutics evaluating pegunigalsidase alfa (PRX-102) an investigational enzyme...
August 31, 2022
(RTTNews) - Regenxbio Inc. (RGNX) Wednesday reported additional positive interim data from the Phase I/II/III CAMPSIITE study of its drug candidat...
August 31, 2022
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022 - read this article along with other careers information, tips and advice on BioSpace
August 30, 2022
Aeglea BioTherapeutics Inc. (AGLE) is priced at $0.60 after the most recent trading session. At the very opening of the session, the stock price was $0.54 and reached a high price of $0.61, prior to closing the session it reached the value of $0.52. The stock touched a low price of $0.53.Recently in